MetVital, Inc. Announces Collaboration with the National Institute of Neurological Disorders and Stroke (part of the NIH) in the Epilepsy Therapy Screening Program (ETSP)
July 23, 2020
MetVital, Inc. Announces FDA Fast Track Designation of Anhydrous Enol-Oxaloacetate (AEO) for the Treatment of Patients with Newly Diagnosed Glioblastoma Multiforme
June 18, 2020 – As seen in Biospace, San Diego Biotechnology Network, Targeted Oncology and more.
MetVital, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for AEO for Phase 2 testing for Glioblastoma Multiforme
June 11, 2019 – As seen in Business Insider, MarketWatch, Yahoo! Finance and more.